-
Oct 23, 2026ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, a PSMA-targeted radioconjugate in patients with mCRPC – Dose escalation results
London, United Kingdom – October 23, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage global radiopharmaceutical company, today announced encouraging preliminary data from its ongoing Phase 1 dose-escalation study of [225Ac]Ac-FL-020, an investigational prostate-specific membrane antigen ("PSMA")-targeted alpha radiopharmaceutical, in patients with metastatic castration-resistant prostate cancer ("mCRPC").
Read More -
Jun 11, 2024Development of 177Lu-FL-091 for the treatment of NTSR1-positive cancers
Shanghai, China, and Heidelberg, Germany – June 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI (The Society of Nuclear Medicine and Molecular Imaging) Annual Meeting, held on June 8th to 11th, 2024 at Metro Toronto Convention Centre, Toronto, ON, Canada.
Read More -
Apr 10, 2024225Ac-FL-020 is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity
Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
Read More